Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.47 USD
Change Today +0.47 / 3.36%
Volume 34.9K
CORI On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 3:43 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Open
$14.00
Previous Close
$14.00
Day High
$15.50
Day Low
$14.00
52 Week High
06/1/15 - $15.98
52 Week Low
11/17/14 - $4.30
Market Cap
262.8M
Average Volume 10 Days
59.8K
EPS TTM
$-1.45
Shares Outstanding
18.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORIUM INTERNATIONAL INC (CORI)

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Corium International, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

Corium International, Inc. announced unaudited earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company’s total revenues were $10,598,000 compared to $10,183,000 a year ago. Loss from operations was $3,994,000 compared to $3,397,000 a year ago. Loss before income taxes was $5,914,000 compared to $4,981,000 a year ago. Net loss and comprehensive loss was $5,914,000 or $0.33 per diluted share compared to $4,981,000 or $0.28 per diluted share a year ago. The increase in total revenues primarily resulted from growth in contract research and development revenues, as well as recognition of a new consumer product launch milestone, partially offset by the continued declines in product revenues from Fentanyl TDS (marketed by Par Pharmaceutical) and Clonidine TDS (marketed by Teva Pharmaceuticals). For the nine months, the company’s total revenues were $31,655,000 compared to $31,368,000 a year ago. Loss from operations was $14,334,000 compared to $5,253,000 a year ago. Loss before income taxes was $19,813,000 compared to $3,545,000 a year ago. Net loss and comprehensive loss was $19,815,000 or $1.10 per diluted share compared to net loss and comprehensive loss of $3,545,000 or $0.48 per diluted share a year ago. The increase in total revenues primarily reflects an increase in contract research and development revenues from co-development and partner funded programs, partially offset by expected declines in product revenues from Fentanyl TDS and Clonidine TDS. Corium would have recognized a non-GAAP net loss of $10.9 million for the nine months ended June 30, 2014.

Corium International, Inc., Q3 2015 Earnings Call, Jul 29, 2015

Corium International, Inc., Q3 2015 Earnings Call, Jul 29, 2015

Corium International, Inc. Announces Positive Topline Results From Phase 2a Study of Transdermal MicroCor PTH in Post-Menopausal Women

Corium International, Inc. announced positive topline interim results from its Phase 2a study designed to determine the pharmacokinetics (PK), pharmacodynamics (PD) and safety and tolerability of its MicroCor transdermal system for the rapid delivery of a treatment for osteoporosis. The product delivers human parathyroid hormone, or hPTH(1-34) (known as teriparatide), a peptide that has been clinically proven to stimulate formation of new bone and reduce the risk of fractures. Teriparatide is approved for the treatment of osteoporosis by the U.S. Food and Drug Administration (FDA) as a daily injection. The MicroCor transdermal system uses a novel biodegradable microstructure technology capable of delivering a wide range of drugs as an alternative to daily injections. The Phase 2a study was conducted as a two-part clinical trial: Part A was designed to evaluate single dose PK and the safety and tolerability of MicroCor PTH in healthy post-menopausal women, compared to the only approved hPTH(1-34) therapy, Eli Lilly's Forteo (teriparatide (rDNA origin) injection); Part B of the study was designed to evaluate the PK and the safety and tolerability of PTH delivered for 28 consecutive days via either the MicroCor needle-free system or Forteo subcutaneous injection. Doses were initially administered at the investigational site followed by self-administration at home or in the clinic for a total of 28 days per subject. PD was evaluated by measuring changes in levels of well-characterized bone biomarkers. Key topline results from the Phase 2a study: Rapid uptake and clearance of hPTH(1-34) in a pulsatile delivery profile was demonstrated in the blood concentrations of all subjects treated with the MicroCor PTH system. Pulsatile delivery of hPTH(1-34) is known to be an important factor in stimulating bone formation; the PK profiles in the 33 subjects aged 50-85 treated with MicroCor in the Phase 2a study were consistent with those of the 16 subjects aged 18-35 treated in the Phase 1 study, demonstrating the reproducibility of the MicroCor system's rapid-onset capability across a wide range of ages; the PK profile of MicroCor PTH was dose proportional across the two doses administered in the study; subjects exhibited similar PK profiles at Day 1 of treatment compared to Day 28, indicating the absence of drug accumulation from sequential daily treatments; increases in serum concentrations of bone-formation markers that are widely understood to be consistent with bone-building activity were comparable among subjects treated with MicroCor PTH and those treated with Forteo injections; subjects treated with MicroCor PTH experienced excellent skin tolerability and no systemic adverse events beyond those observed in subjects treated with Forteo injections. All subjects treated with MicroCor PTH completed the trial; results support advancing the MicroCor PTH transdermal system into late-stage clinical development in osteoporotic patients. Study Design: the study was performed at a single trial site in Australia and enrolled 39 postmenopausal women aged 50 to 85 (mean age of 63 years). Part A of the study was a single-dose, crossover study of 18 subjects. Subjects were randomized to one of the three initial treatment arms: MicroCor PTH 16 mcg, MicroCor PTH 38 mcg or Forteo® 20 mcg injection. The primary objective was to assess the single dose PK of MicroCor PTH compared to Forteo injection. The secondary objectives were assessment of safety and tolerability and dose proportionality between the 16 mcg and 38 mcg MicroCor PTH systems. Part B of the study was a 28-day, multiple dose, parallel group study of 21 subjects. All study participants were taught self-administration techniques in a clinical setting, after which they self-administered their medication at home or in the clinic. Subjects were randomized to two treatment groups: MicroCor PTH 38 mcg, or Forteo 20 mcg injection. The MicroCor PTH patch was applied to a naïve skin site on the lateral abdomen for five minutes on a daily basis for 28 days. The Forteo 20 mcg/daily injection was administered in the abdomen wall. Study participants were assessed periodically at the clinic after randomization. The primary objective was to assess the multiple dose PK of MicroCor PTH compared to Forteo injections. The secondary objectives were assessment of safety and tolerability and changes in serum levels of bone biomarkers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $14.47 USD +0.47

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $152.14 USD +0.14
FUJIFILM Holdings Corp ¥4,920 JPY +358.00
Mylan NV $55.91 USD -0.44
Zogenix Inc $19.23 USD -0.08
Zosano Pharma Corp $7.83 USD +0.1199
View Industry Companies
 

Industry Analysis

CORI

Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit www.coriumgroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.